mTOR inhibitors in cancer therapy

被引：259
|
作者：
Zaytseva, Yekaterina Y. [1 ]
Valentino, Joseph D. [1 ,2 ]
Gulhati, Pat [3 ]
Evers, B. Mark [1 ,2 ]
机构：
[1] Univ Kentucky, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA
[2] Univ Kentucky, Dept Surg, Lexington, KY 40536 USA
[3] Univ Texas Med Branch, MD PhD Program, Galveston, TX USA
来源：
CANCER LETTERS | 2012年 / 319卷 / 01期
关键词：
mTOR; Cancer; Cancer therapy; Drug resistance; DUAL PI3K/MTOR INHIBITOR; MAMMALIAN TARGET; CELL MOTILITY; COMPLEX; GROWTH; ACTIVATION; PROLIFERATION; PATHWAY; PHOSPHORYLATION; RICTOR;
D O I：
10.1016/j.canlet.2012.01.005
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The mammalian target of rapamycin (mTOR) plays a key role in regulation of cellular metabolism, growth, and proliferation. The frequent hyperactivation of mTOR signaling makes it an attractive target for therapeutic intervention and has driven the development of a number of mTOR inhibitors. Encouraging data from preclinical studies have resulted in initiation of multiple clinical trials. Furthermore, combinational strategies are being studied in an effort to overcome resistance and enhance efficacy. Although additional studies are required to determine their specific role in the clinical setting, mTOR inhibitors remain a promising therapeutic option for the treatment of cancer. (c) 2012 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码：1 / 7
页数：7
相关论文
共 50 条
  • [31] Updating progress in sarcoma therapy with mTOR inhibitors
    Blay, J. -Y.
    ANNALS OF ONCOLOGY, 2011, 22 (02) : 280 - 287
  • [32] Targeting mTOR for cancer therapy
    Hui Hua
    Qingbin Kong
    Hongying Zhang
    Jiao Wang
    Ting Luo
    Yangfu Jiang
    Journal of Hematology & Oncology, 12
  • [33] mTOR as a target for cancer therapy
    Houghton, PJ
    Huang, S
    TOR-TARGET OF RAPAMYCIN, 2003, 279 : 339 - 359
  • [34] Targeting mTOR for cancer therapy
    Hua, Hui
    Kong, Qingbin
    Zhang, Hongying
    Wang, Jiao
    Luo, Ting
    Jiang, Yangfu
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (1)
  • [35] mTOR as a target for cancer therapy
    Houghton, Peter J.
    ACTA PHARMACOLOGICA SINICA, 2006, 27 : 2 - 2
  • [36] mTOR inhibitors in breast cancer: A systematic review
    Zagouri, Flora
    Sergentanis, Theodoros N.
    Chrysikos, Dimosthenis
    Filipits, Martin
    Bartsch, Rupert
    GYNECOLOGIC ONCOLOGY, 2012, 127 (03) : 662 - 672
  • [37] Clinical Development of mTOR Inhibitors in Breast Cancer
    Andre, F.
    CANCER RESEARCH, 2012, 72
  • [38] A Review of mTOR Pathway Inhibitors in Gynecologic Cancer
    de Melo, Andreia Cristina
    Paulino, Eduardo
    Ingles Garces, Alvaro Henrique
    OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2017, 2017
  • [39] The promise of mTOR inhibitors in the treatment of colorectal cancer
    Kim, Dae-Dong
    Eng, Cathy
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2012, 21 (12) : 1775 - 1788
  • [40] The therapeutic potential of mTOR inhibitors in breast cancer
    Steelman, Linda S.
    Martelli, Alberto M.
    Cocco, Lucio
    Libra, Massimo
    Nicoletti, Ferdinando
    Abrams, Stephen L.
    McCubrey, James A.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 82 (05) : 1189 - 1212
12345